|
| related topics |
| {product, candidate, development} |
| {product, liability, claim} |
| {regulation, government, change} |
| {system, service, information} |
| {customer, product, revenue} |
| {operation, international, foreign} |
| {condition, economic, financial} |
| {financial, litigation, operation} |
| {acquisition, growth, future} |
|
|
We face intense competition from other pharmaceutical manufacturers, including both innovative medicines and lower-priced generic products.
We depend on key products for most of our net sales, cash flows and earnings.
It is possible that we may lose market exclusivity of a product earlier than expected.
Data protection for PLAVIX* has expired in the EU and PLAVIX* faces competition in European markets.
U.S. and foreign laws and regulations may negatively affect our net sales and profit margins.
Our business and results of operations could be adversely affected by pending healthcare reform legislation in the U.S.
We face increased pricing pressure in the U.S. and abroad from managed care organizations, institutional purchasers, and government agencies and programs that could negatively affect our net sales and profit margins.
Changes to the product label for any of our marketed products or results from certain studies released after a product is approved could potentially have a negative impact on sales of that product.
We may experience difficulties and delays in the manufacturing, distribution and sale of our products.
We may experience difficulties or delays in the development and commercialization of new products.
There are legal matters in which adverse outcomes could negatively affect our business.
We rely on third parties to meet their contractual, regulatory, and other obligations.
Failure to execute our business strategy could adversely impact our growth and profitability.
We are increasingly dependent on our outsourcing arrangements.
We are increasingly dependent on information technology.
Adverse changes in U.S., global, or regional economic conditions could have a continuing adverse effect on the profitability of some or all of our businesses.
Changes in foreign currency exchange rates and interest rates could have a material adverse effect on our results of operations.
The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.
Full 10-K form ▸
|
|
| related documents |
| 14272--2/20/2009--BRISTOL_MYERS_SQUIBB_CO |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 810509--3/31/2008--NEOPROBE_CORP |
| 1020214--3/11/2010--CERUS_CORP |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 1000694--3/6/2006--NOVAVAX_INC |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 310158--2/28/2006--SCHERING_PLOUGH_CORP |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 943736--3/31/2006--MED-DESIGN_CORP |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 824068--3/12/2010--ATS_MEDICAL_INC |
| 918112--11/6/2006--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/ |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 1041024--3/12/2010--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 881890--6/14/2010--ABAXIS_INC |
| 64978--2/27/2009--MERCK_&_CO_INC |
| 1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 881890--6/12/2009--ABAXIS_INC |
| 887247--3/20/2008--CELLEGY_PHARMACEUTICALS_INC |
| 749647--3/17/2010--Celsion_CORP |
| 817785--3/28/2006--IMMUNE_RESPONSE_CORP |
| 1034682--9/29/2008--HERITAGE_WORLDWIDE_INC |
| 908259--3/14/2007--OXIGENE_INC |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
|